Oritel M 40mg/25mg Tablet is a combination antihypertensive medication containing Telmisartan 40mg and Metoprolol Succinate 25mg. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac function. This combination is indicated for the management of hypertension, providing complementary mechanisms to achieve effective blood pressure control and reduce the risk of cardiovascular events such as stroke, myocardial infarction, and heart failure. Oritel M is particularly beneficial in patients requiring dual therapy for hypertension who may also have concomitant cardiac conditions such as angina or post-myocardial infarction status. The tablet should be administered once daily, with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with bradycardia, heart block, severe hepatic or renal impairment, and in those with a history of hypersensitivity to either component. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during treatment.